Gilead HCV Heart and Lung - A Multicenter, open-label study of Harvoni® (sofosbuvir-ledipasvir fixed dose combination) in subjects infected with chronic hepatitis C and advanced heart failure or lung disease

Administered By

Awarded By

Contributors

Start/End

  • September 1, 2016 - August 31, 2020